Nexotrav (Timolol, Travoprost)

Timolol and Travoprost, the active ingredients in Nexotrav, are a beta‑blocker and prostaglandin analog presented as eye drops for ocular use. They treat open‑angle glaucoma and ocular hypertension in adult patients. GNH USA supplies Nexotrav as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nexotrav is indicated for conditions affecting intraocular pressure within the glaucoma disease family.

Open‑angle glaucoma: lowers intraocular pressure to slow disease progression. Ocular hypertension: reduces pressure to prevent development of glaucoma. Elevated intraocular pressure in patients at risk of glaucoma: helps maintain target pressure and protect optic nerve health.

Nexotrav may cause ocular and systemic adverse reactions.

Common Side Effects: - Eye irritation or burning sensation. - Redness (hyperemia) of the conjunctiva. - Blurred vision shortly after instillation. - Itching or mild allergic conjunctivitis. - Increased eyelash growth. - Dry eye sensation.

Serious or Rare Side Effects: - Severe allergic reaction with swelling of the eyelid or face. - Sudden loss of vision or acute ocular pain. - Systemic beta‑blocker effects such as bradycardia, hypotension, or bronchospasm. - Persistent corneal edema or ulceration. - Worsening of pre‑existing respiratory conditions.

Before prescribing Nexotrav, clinicians should evaluate patient-specific risk factors.

Assess cardiovascular status: timolol may lower heart rate and blood pressure. Screen for asthma or COPD: beta‑blockade can precipitate bronchospasm. Monitor intraocular pressure response after initiation. Avoid use in patients with known hypersensitivity to any component. Consider pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at room temperature: keep in original container, protect from light and moisture.

Nexotrav can interact with systemic and ocular medications.

Major Interactions (Avoid): - Systemic non‑selective beta‑blockers: additive bradycardia or hypotension. - Other prostaglandin analog eye drops: increased risk of ocular side effects. - Sympathomimetic ocular agents (e.g., phenylephrine): may reduce IOP‑lowering efficacy.

Moderate Interactions (Monitor Closely):\n- Anticholinergic eye drops: may affect pupil size and comfort. - Topical anesthetics: potential for increased corneal toxicity. - Systemic carbonic anhydrase inhibitors: additive intraocular pressure reduction.